News
IKT
1.325
+1.92%
0.025
Analysts Conflicted on These NA Names: INNIO Holding GmbH (INIO), Inhibikase Therapeutics (IKT) and Sunrise Communications AG Class A (OtherSNNRF)
TipRanks · 4d ago
Weekly Report: what happened at IKT last week (1109-1113)?
Weekly Report · 4d ago
Analysts Conflicted on These NA Names: Generate Biomedicines, Inc. (GENB), Inhibikase Therapeutics (IKT) and Yesway Inc Class A (YSWY)
TipRanks · 11/13 13:50
Inhibikase Therapeutics Is Maintained at Neutral by Chardan Capital
Dow Jones · 11/12 19:59
Inhibikase Therapeutics Price Target Maintained With a $1.50/Share by Chardan Capital
Dow Jones · 11/12 19:59
Inhibikase’s PAH Program Advances, Supporting Buy Rating and Unchanged $8 Price Target
TipRanks · 11/12 18:55
HC Wainwright & Co. Reiterates Buy on Inhibikase Therapeutics, Maintains $8 Price Target
Benzinga · 11/12 13:15
Analysts Offer Insights on NA Companies: Lucid Group (LCID) and Inhibikase Therapeutics (IKT)
TipRanks · 11/11 13:30
Inhibikase Therapeutics GAAP EPS of -$0.10 beats by $0.01
Seeking Alpha · 11/10 22:03
*Inhibikase Therapeutics 3Q Loss/Shr 10c >IKT
Dow Jones · 11/10 21:06
Press Release: Inhibikase Therapeutics Announces -2-
Dow Jones · 11/10 21:01
Press Release: Inhibikase Therapeutics Announces Third Quarter 2026 Financial Results and Highlights Recent Activity
Dow Jones · 11/10 21:01
Press Release: Inhibikase Therapeutics Announces -3-
Dow Jones · 11/10 21:01
Weekly Report: what happened at IKT last week (1102-1106)?
Weekly Report · 11/09 09:10
Weekly Report: what happened at IKT last week (1026-1030)?
Weekly Report · 11/02 09:10
Weekly Report: what happened at IKT last week (1019-1023)?
Weekly Report · 10/26 09:10
Inhibikase Appoints Scott Wasserman to Board of Directors
TipRanks · 10/20 21:17
Inhibikase Therapeutics appoints Kailera CMO Scott Wasserman to board
TipRanks · 10/20 20:05
*Inhibikase Therapeutics Appoints Scott Wasserman to Bd of Directors
Dow Jones · 10/20 20:04
*Inhibikase Therapeutics: Dennis Berman Resigned From the Bd >IKT
Dow Jones · 10/20 20:04
More
Webull provides a variety of real-time IKT stock news. You can receive the latest news about Inhibikase Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About IKT
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).